Ismail, Usama
Rowe, Roger A.
Cashin, John
Genin, Guy M.
Zayed, Mohamed A.
Funding for this research was provided by:
Skandalaris Center (LEAP award)
NIH/NHLBI (R41 HL 150963)
Article History
Received: 19 September 2021
Accepted: 4 March 2022
First Online: 28 March 2022
Competing interests
: G.M.G. and M.A.Z. have equity in Caeli Vascular, Inc., which specializes in developing treatments for venous disease. U.I. and R.A.R are employed by Caeli Vascular, Inc.